Table 3.
Relative Risk of Colorectal Cancer According to Plasma Adiponectin and Soluble Leptin Receptor in the Nurses’ Health Study (1990–2008) and Health Professionals Follow-up Study (1994–2008)
| Qa | Medianb | No. of Cases | No. of Controls | Model 1c
|
Model 2d
|
Model 3e
|
|---|---|---|---|---|---|---|
| RR (95% CI) | RR (95% CI) | RR (95% CI) | ||||
| Adiponectin, μg/mL | ||||||
| Women | ||||||
| Q1 | 4.56, 4.01 | 103 | 172 | 1.00 (Referent) | 1.00 (Referent) | 1.00 (Referent) |
| Q2 | 7.05, 7.28 | 77 | 172 | 0.75 (0.52, 1.08) | 0.80 (0.55, 1.17) | 0.82 (0.56, 1.20) |
| Q3 | 9.50, 9.07 | 74 | 171 | 0.72 (0.50, 1.05) | 0.71 (0.49, 1.04) | 0.74 (0.51, 1.10) |
| Q4 | 12.7, 12.5 | 92 | 171 | 0.90 (0.63, 1.29) | 0.96 (0.67, 1.39) | 1.01 (0.69, 1.49) |
| Ptrendf | 0.59 | 0.74 | 0.99 | |||
| Men | ||||||
| Q1 | 3.00 | 88 | 129 | 1.00 (Referent) | 1.00 (Referent) | 1.00 (Referent) |
| Q2 | 4.50 | 61 | 130 | 0.68 (0.46, 1.03) | 0.69 (0.46, 1.05) | 0.71 (0.47, 1.08) |
| Q3 | 6.18 | 75 | 130 | 0.83 (0.56, 1.24) | 0.88 (0.59, 1.33) | 0.92 (0.61, 1.39) |
| Q4 | 9.95 | 46 | 130 | 0.51 (0.33, 0.79) | 0.55 (0.35, 0.86) | 0.61 (0.38, 0.96) |
| Ptrendf | 0.007 | 0.02 | 0.07 | |||
| Soluble Leptin Receptor, ng/mL | ||||||
| Women | ||||||
| Q1 | 23.7, 25.7 | 84 | 94 | 1.00 (Referent) | 1.00 (Referent) | 1.00 (Referent) |
| Q2 | 29.0, 30.7 | 72 | 92 | 0.88 (0.57, 1.35) | 0.89 (0.58, 1.39) | 0.93 (0.60, 1.45) |
| Q3 | 34.6, 37.1 | 102 | 93 | 1.24 (0.82, 1.87) | 1.32 (0.86, 2.03) | 1.40 (0.91, 2.18) |
| Q4 | 44.8, 46.0 | 82 | 92 | 0.99 (0.65, 1.51) | 1.11 (0.71, 1.75) | 1.23 (0.77, 1.97) |
| Ptrendf | 0.79 | 0.81 | 0.53 | |||
| Men | ||||||
| Q1 | 19.4 | 83 | 129 | 1.00 (Referent) | 1.00 (Referent) | 1.00 (Referent) |
| Q2 | 24.2 | 70 | 130 | 0.83 (0.56, 1.25) | 0.80 (0.53, 1.21) | 0.85 (0.56, 1.29) |
| Q3 | 28.2 | 66 | 130 | 0.79 (0.52, 1.18) | 0.80 (0.53, 1.23) | 0.89 (0.58, 1.38) |
| Q4 | 36.2 | 51 | 130 | 0.61 (0.40, 0.93) | 0.66 (0.42, 1.04) | 0.77 (0.48, 1.24) |
| Ptrendf | 0.02 | 0.09 | 0.33 | |||
Abbreviation: CI, confidence interval; Q, quartile; RR, relative risk.
Quartiles and their medians of plasma markers were based on the distribution among the control participants. For the Nurses’ Health Study in women, the run-specific cutoff points were used.
For the Nurses’ Health Study in women, the median values of each quartile separately for the two runs (1990–2004, 2006–2008) are given.
Adjusted for matching factors (age at blood draw and date of blood draw).
Adjusted for matching factors (age at blood draw and date of blood draw), fasting status of blood collection, colorectal cancer in parent or sibling, prior lower gastrointestinal endoscopy, history of polyp, regular use of multivitamins, pack-years of smoking (never smoking, <10, 10–24, 25–49, ≥50 pack-years), alcohol consumption (0, 0–5, 5–15, >15g/day), physical activity (tertile, metabolic equivalent hours per week), regular aspirin/NSAID use (≥2 tablets/week), plasma 25-hydroxyvitamin D (tertile, ng/mL), and Dietary Approaches to Stop Hypertension (DASH) score (quartile). In NHS, menopausal status and current postmenopausal hormone use were additionally adjusted.
Additionally adjusted for body mass index (kg/m2).
Tests for trend were conducted using the median values for each quartile of analyte.